Donato Leslie J, Meeusen Jeffrey W, Jenkins Sarah M, Hartman Stacy J, Saenger Amy K, Baumann Nikola A, Block Darci R, Jaffe Allan S
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, United States.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, United States.
Clin Biochem. 2017 Apr;50(6):347-349. doi: 10.1016/j.clinbiochem.2016.11.028. Epub 2016 Nov 25.
Measuring lipoprotein-associated phospholipase A (Lp-PLA) activity can aid in identifying individuals at higher risk of coronary heart disease. However, the biological variation of Lp-PLA activity and corresponding reference change value (RCV) is unknown which limits interpretation of results. In this study we aim to define the intra- and inter-individual variability of Lp-PLA activity in a healthy reference population.
A total of 24 healthy individuals (22-47years of age) were prospectively collected at several time points: daily for five days (after overnight fast), daily for three days (while non-fasting), weekly for four weeks (after overnight fast), and monthly for 6months (after overnight fast). Intra-individual and inter-individual variability was determined. The index of individuality (IoI) and reference change value (RCV) were calculated for each time period.
Variability in Lp-PLA activity was not different in fasting versus non-fasting states and also did not change in daily versus monthly testing. The RCV for monthly Lp-PLA activity was found to be 17%. More than 90% of the variability was attributable to between person differences while analytic variability comprised <9% of the variability and within-person variability was low at <0.7%. The index of individuality for monthly testing was 0.30 CONCLUSIONS: In a healthy population, Lp-PLA activity displays low analytical and within-person variability and higher inter-individual variability. The change required to differentiate a true change in patient status was determined to be 17% for monthly measurements. The between individual variability and corresponding RCV for the activity assay are lower than previously reported results for the Lp-PLA mass assay.
测量脂蛋白相关磷脂酶A(Lp-PLA)活性有助于识别冠心病风险较高的个体。然而,Lp-PLA活性的生物学变异及相应的参考变化值(RCV)尚不清楚,这限制了对结果的解读。在本研究中,我们旨在确定健康参考人群中Lp-PLA活性的个体内和个体间变异性。
前瞻性收集了24名健康个体(22 - 47岁)在多个时间点的数据:连续5天每天(过夜禁食后)、连续3天每天(非禁食时)、连续4周每周(过夜禁食后)以及连续6个月每月(过夜禁食后)。确定个体内和个体间变异性。计算每个时间段的个体性指数(IoI)和参考变化值(RCV)。
Lp-PLA活性在禁食与非禁食状态下的变异性无差异,每日检测与每月检测时也未发生变化。发现每月Lp-PLA活性的RCV为17%。超过90%的变异性归因于个体间差异,而分析变异性占变异性的比例小于9%,个体内变异性较低,低于0.7%。每月检测的个体性指数为0.30。结论:在健康人群中,Lp-PLA活性表现出低分析变异性和个体内变异性,以及较高的个体间变异性。确定每月测量时区分患者状态真正变化所需的变化为17%。该活性测定的个体间变异性和相应的RCV低于先前报道的Lp-PLA质量测定结果。